Loading organizations...
Based in Zürich, Switzerland, EVis Bioscience develops advanced non-viral gene delivery systems utilizing extracellular vesicles loaded with RNA through its proprietary EVis NanoVector platform. The biotechnology company generates recurring revenue by licensing its delivery technology, providing specialized research services, and forming strategic research and development collaborations with pharmaceutical companies to advance targeted gene therapies for genetic diseases. Operating as a spin-out from the Swiss research university ETH Zürich, the enterprise successfully secured €740,000 in pre-seed funding through the European healthcare investment platform Capital Cell in March 2026. This initial capital supports the advancement of their proprietary therapeutics into preclinical stages while expanding their commercial partnerships across the broader drug discovery, medical technology, and nanotechnology sectors. EVis Bioscience was established in June 2024 by the founding team of Elita Montanari, Gianfranco Vento, and Tommaso Caselli.
EVis Bioscience has raised $85.0M across 1 funding round.
EVis Bioscience has raised $85.0M in total across 1 funding round.
EVis Bioscience has raised $85.0M across 1 funding round. Most recently, it raised $85.0M Pre-Seed in March 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 20, 2026 | $85M Pre Seed | — | — | Announced |
EVis Bioscience has raised $85.0M in total across 1 funding round.